SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
INSM reported Third quarter ended September 30, 2026 results. The stock moved +15.1% on the print.
INSMearnings

Earnings reactions, page 9

Insmed Incorporated (INSM) Q3 FY2026 earnings

October 29, 2026 · SharpeIQ Research Desk

Reported results

  • Total company revenues were $524.4 million for the third quarter of 2026.
  • BRINSUPRI revenues were $400.1 million for the third quarter of 2026.
  • ARIKAYCE revenues were $124.4 million for the third quarter of 2026.
  • Net loss was $100.3 million, or $0.46 per share, for the third quarter of 2026.
  • Research and development (R&D) expenses were $270.0 million for the third quarter of 2026.
  • Selling, general and administrative (SG&A) expenses were $253.0 million for the third quarter of 2026.

Guidance

  • 2026 BRINSUPRI revenue guidance: $1.35 billion to $1.4 billion
  • 2026 ARIKAYCE revenue guidance: $460 million to $470 million

Price and volatility reaction

The stock moved +15.1% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -31.9 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release96.982026-10-28
Close after release111.592026-10-29
Realised move+15.1%close to close
30d ATM IV change-31.9 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →